Sangamo Therapeutics, Inc. Q3 2025 Earnings Recap

SGMO Q3 2025 November 7, 2025

Get alerts when SGMO reports next quarter

Sangamo Therapeutics reported significant advancements in its clinical pipeline for Fabry disease, highlighted by promising data from its STAAR study and a positive interaction with the FDA regarding its upcoming BLA submission.

Earnings Per Share Miss

$-0.11 vs $-0.03 est.

-266.7% surprise

Revenue Miss

581000 vs 40250000 est.

-98.6% surprise

Market Reaction

1-Day +2.45%

5-Day +2.06%

30-Day -4.41%

See SGMO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Presented compelling clinical data from the STAAR study, showing durable benefits of ST-920, with a mean annualized eGFR slope of nearly 2 at 52 weeks across all patients.
FDA meeting confirmed agreement to use eGFR slope as an endpoint for an accelerated approval pathway, with plans for a BLA submission anticipated in early 2026.
Initiated the Phase I/II STAND study for chronic neuropathic pain, expanding Sangamo's reach into neurology.
Emphasized the strong safety profile and durable efficacy of ST-920, including encouraging cardiac data from treated patients.
Focused commitment to addressing unmet needs within the Fabry community, bolstered by patient engagement and feedback.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SGMO on AllInvestView.

Next Q1 2026